Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75,640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.
Feng W, Chen X, Guan SX, Ruan HL, Huang Y, Zhang HZ, Yang YP, Fang WF, Zhao HY, Zhuang W, Xin S, Chen YH, Wang F, Gao Y, Huang M, Wang XD, Zhang L. Feng W, et al. Among authors: huang m, huang y. Acta Pharmacol Sin. 2022 Jul;43(7):1857-1864. doi: 10.1038/s41401-021-00791-5. Epub 2021 Nov 4. Acta Pharmacol Sin. 2022. PMID: 34737420 Free PMC article.
Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer.
Guan S, Chen X, Xin S, Liu S, Yang Y, Fang W, Huang Y, Zhao H, Zhu X, Zhuang W, Wang F, Feng W, Zhang X, Huang M, Wang X, Zhang L. Guan S, et al. Among authors: huang m, huang y. Transl Oncol. 2021 Jan;14(1):100951. doi: 10.1016/j.tranon.2020.100951. Epub 2020 Nov 19. Transl Oncol. 2021. PMID: 33221684 Free PMC article.
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, Zhao H, Hong S, Zhang L. Zhou Y, et al. Among authors: huang y. J Immunother Cancer. 2018 Dec 22;6(1):155. doi: 10.1186/s40425-018-0477-9. J Immunother Cancer. 2018. PMID: 30577837 Free PMC article.
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis.
Zhang Z, Zeng K, Zhao S, Zhao Y, Hou X, Luo F, Lu F, Zhang Y, Zhou T, Ma Y, Yang Y, Fang W, Huang Y, Zhang L, Zhao H. Zhang Z, et al. Among authors: huang y. Ther Adv Med Oncol. 2019 Dec 30;11:1758835919891652. doi: 10.1177/1758835919891652. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31908655 Free PMC article.
75,640 results
You have reached the last available page of results. Please see the User Guide for more information.